ArticleClinical and experimental medicine2025
The potential mechanism and immunomodulatory effect of gut microbiota-derived metabolites in the treatment of gastric cancer by integrating network pharmacology and molecular docking.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer is a malignant tumor that seriously threatens human health. In this study, we explored the potential mechanism and immunomodulatory effects of gut microbiota (GM) metabolites on gastric cancer through network pharmacology and molecular docking. The GM metabolites, targets of GM metabolites and gastric cancer were obtained from the public databases. The cross-targets of GM metabolites and gastric cancer were analyzed and the common key targets were further got. GO function and KEGG analysis were conducted to identify potential functions and regulatory mechanisms. A GMMTGM network was built, and then the drug likeness and toxicity of obtained GM metabolites were screened. The molecular docking was employed to assess binding affinity between GM metabolites and corresponding targets. The expression of key targets was validated, and the relationship between key targets with immune cell infiltration levels and immune checkpoints was analyzed in gastric cancer. We identified eight overlapping key targets between GM metabolites and gastric cancer. HIF-1 and TNF signaling pathways were the main signaling pathways. Furthermore, nine GM metabolites were expected to be as drug‑likeness and low-toxicity compounds, and six GM metabolites had good binding affinity with corresponding protein, and their binding affinities under - 5 kcal/mol. The expressions of AKT1, CASP3, GAPDH, HIF1A and STAT3 in gastric cancer and normal sample were statistically significant (P < 0.01). Moreover, the results of immune-related analysis showed that key genes may mediate the occurrence and development of gastric cancer by influencing the immune cell infiltration levels and immune checkpoints. GM metabolites primarily exert their therapeutic effects on gastric cancer through multiple targets, pathways, immune cell infiltration levels and immune checkpoints. Further in vitro and in vivo studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.